Semaglutide 2mg Injection: The Third Step in Your Wegovy Dose Ladder

Step 1: Understanding the titration sequence before you worry about the number

If you arrived here searching for a 2mg semaglutide injection, you are probably mid-titration and wondering whether the dose you have just been prescribed is right, or you spotted the figure on a box and wanted to cross-check it. That is entirely reasonable. The Wegovy schedule does pass through what some packaging and labelling rounds to roughly 2mg territory as it climbs toward 2.4mg, and if you want to understand exactly what the Wegovy 2mg pen contains and how it fits into the sequence, that page explains it clearly. The UK-licensed steps are fixed: 0.25mg, then 0.5mg, 1mg, 1.7mg, and finally 2.4mg. There is no formally named 2mg resting stage.

Each step is designed to give your body four weeks to adjust. The lower doses are not therapeutic in the weight-loss sense; their job is to reduce the nausea, bloating and digestive disruption that can otherwise hit hard if you start at a higher level. The NHS semaglutide medicines page sets this out clearly. Moving up the schedule is a clinical decision, not an automatic one, if side effects are significant at 1.7mg, a prescriber may hold you there longer before any move upward.

This is also why treating the number on the pen as a performance metric misses the point. Reaching 2.4mg faster does not mean better results; it means a higher risk of unpleasant early side effects that push people to stop altogether.

Step 2: What the evidence says about reaching and staying at maintenance dose

The data behind Wegovy comes primarily from the STEP programme. In STEP 1, published in the New England Journal of Medicine, 68 weeks of once-weekly semaglutide 2.4mg alongside lifestyle changes produced an average body-weight reduction of around 15% in adults with obesity and no diabetes. Participants who lost less than 5% of their body weight after six months on the maintenance dose were typically flagged for review.

That 15% figure is a population average across thousands of participants. Individual results varied, some lost considerably more, some less. Factors like baseline weight, adherence, diet quality and physical activity all played a role. No injection, at any dose, works in isolation from the broader picture.

For context on how Wegovy compares with tirzepatide (Mounjaro) across the same metric, the Wegovy treatment overview covers the head-to-head evidence without overstating what the data can confirm. The short version: both medicines produce clinically meaningful weight loss; the right choice depends on your health history, not a league table.

Step 3: The clinical process for getting each dose dispensed safely

Every supply of Wegovy at any dose point requires a valid prescription. At nume, that means a GPhC-registered Independent Prescriber reads your consultation personally before anything is dispensed, not a screening algorithm, not an automated check. The same review happens at each repeat, because your clinical picture can change between orders.

The practical sequence runs like this. You complete a free consultation online. A prescriber assesses it the same day. If suitable, and if you order before midday on a working day, your treatment is dispatched the same day and arrives the next working day via DPD, in plain unbranded packaging. There are no subscription commitments; every order is reviewed fresh. You can read more about how the process is set up on the about us page, or explore the full guide to injecting semaglutide correctly once your prescription is in place.

If you are considering switching from injections to a non-injection option, oral semaglutide (Wegovy tablets) received MHRA approval in June 2026 as the first licensed oral GLP-1 for weight management in the UK. The non-injection semaglutide page explains how it differs in dosing and absorption.

Step 4: Practical storage and safety points at the 1.7mg and 2.4mg stages

Higher doses tend to bring a sharper focus on storage, partly because the pens are more expensive to replace if something goes wrong. Wegovy pens must be refrigerated at 2–8°C. What happens if a pen is left out too long is a question our prescribers hear regularly, the guide on Wegovy temperature exposure covers the specifics, but the short answer is: always follow your Patient Information Leaflet rather than general rules, because the window is precise.

Side effects at the upper doses tend to mirror those at the start of treatment (nausea, loose stools, fatigue, reflux) but are usually briefer because your system has already adapted to the mechanism. Pancreatitis is a less common but serious risk: the MHRA issued a Drug Safety Update in January 2026 specifically flagging GLP-1 medicines and acute pancreatitis, noting that severe stomach pain spreading to the back warrants urgent medical attention. Report any suspected reactions via Yellow Card.

If you are ready to check whether Wegovy is clinically suitable for you at your current dose or as a new patient, speaking to our prescribers is the right next step. Start with the free consultation at our weight-loss treatments page.